Moleculin Biotech (MBRX) Corporate presentation summary

Leadership and experience

• Executive team includes experienced leaders with backgrounds in drug development and multiple FDA approvals.

• Management has over 200 years of combined drug development experience and a track record of successful exits.

Technology and pipeline

• Lead asset Annamycin is a next-generation anthracycline with a novel lipid delivery system and major structural changes.

• Annamycin is positioned as the first non-cardiotoxic anthracycline, showing zero cardiotoxicity in over 100 subjects, even at high doses.

• Pipeline includes additional oncology and virology candidates, such as WP1066 (STAT3 inhibitor) and WP1122 (metabolite), with ongoing clinical and preclinical studies.

• All technology is derived from or jointly developed with MD Anderson Cancer Center.

Clinical development and efficacy

• Annamycin demonstrated a 60% complete remission composite (CRc) and 50% complete remission (CR) in relapsed/refractory AML, with durable responses and improved overall survival.

• Efficacy in venetoclax-resistant AML patients is notably higher than current salvage therapies, with a 40% CR and 60% CRc rate.

• Adaptive Phase 2B/3 MIRACLE trial is underway, with FDA guidance and a low approval bar; two major data readouts expected in 2026.

• Preliminary blinded efficacy in the ongoing trial aligns with management expectations, showing 40% CRc and 30% CR rates.